Hi all,Imagion Biosystem’s Chairman and CEO Bob Proulx recently...

Hi all,

Imagion Biosystem’s Chairman and CEO Bob Proulx recently spoke with The Market Herald on recent activity in the molecular imaging market and the Company’s current business activities, including initiatives related to the HER2 trial and the new collaboration with Patrys.

The announcement of GE’s acquisition of a small PET imaging company is a good indicator that strategic players are placing value on molecular imaging and looking to partner with companies like Imagion to develop and bring diagnostic imaging solutions to the market. We believe that our HER2 Phase I study will be valuable in moving us closer to such strategic relationships and we continue to work on initiatives as communicated in our recent 4C to complete the study. See the interview here: https://jwp.io/s/d0572UZc